CNS Pharmaceuticals
CNSP
1 hedge funds and large institutions have $1.98M invested in CNS Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
980% more capital invested
Capital invested by funds: $183K → $1.98M (+$1.79M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
Altium Capital Management
New York
| $951K | +$1.85M | +1 | New |
|
|
CH
2
CVI Holdings
Wilmington,
Delaware
| $740K | – | – | – |
|
|
EIM
3
Essex Investment Management
Boston,
Massachusetts
| $109K | – | – | – |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $83K | – | – | – |
|
|
WAM
5
Warberg Asset Management
Winnetka,
Illinois
| $25K | – | – | – |
|
6
Morgan Stanley
New York
| $22K | – | – | – |
|
|
IAN
7
Integrated Advisors Network
Dallas,
Texas
| $19K | – | – | – |
|
|
ACI
8
Alpha Cubed Investments
Irvine,
California
| $18K | – | – | – |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $9K | – | – | – |
|
|
CWAF
10
Core Wealth Advisors (Florida)
Lakeland,
Florida
| $1K | – | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$7K | – | – |
|
CNSP Hedge Fund Activity: Q4 2020 in Review
1 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q4 2020, worth a combined $1.98M — up 980% from $183K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CNSP positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest seller was UBS Group, cutting an estimated $7K.
- 1 institutional investor held CNS Pharmaceuticals (CNSP) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $1.98M of CNS Pharmaceuticals stock for Q4 2020, up 980% quarter-over-quarter.
- 1 fund opened new CNS Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +1 holder.
- The largest CNS Pharmaceuticals seller in Q4 2020 was UBS Group, an estimated $7K sold.
Based on aggregated 13F filings for Q4 2020.